Brazil’s health technology assessment institute is to incorporate cost-effectiveness thresholds into its decision making.

Companies selling orphan medicines in the Netherlands need to prepare for the likelihood that their products will enter the so-called lock system, which means they will come under extra scrutiny and take longer to reach patients.

A joint statement from the European Medicines Agency and Heads of Medicines Agencies on biosimilar interchangeability is “concerning,” says Europe’s R&D-based industry federation, EFPIA.

Slovakia has introduced a new system for agreeing managed entry agreements that will make it easier for companies to get their innovative medicines to the market.

New platform for finding solutions to increase access to expensive medicines should ensure sustainability of health care systems and pharmaceutical industry and could include tiered pricing models.

A direct marketing authorization application to the UK medicines regulator offered a quicker route to approval for Novartis’ prostate cancer treatment Pluvicto than following the international Access Consortium process, because of the novel nature of the therapy, according to the company.